The pulmonary microvascular endothelial barrier function is controlled by the PGE 2 -EP 4 signaling axis 
Methods
The endothelial barrier properties were analyzed by measurements of transendothelial electrical resistance (TEER) by Endohm and by ECIS (Electric Cell substrate Impedance Sensing) devices. Morphological studies were performed with immunofluorescence microscopy. Different protein expressions were detected by flow cytometry. Leukocyte diapedesis was studied by performing transendothelial migration assays of neutrophils and eosinophils.
Results
We found that the EP 4 receptor is expressed on HMVEC-L. PGE 2 and the selective EP 4 receptor agonist (ONO-AE1-329) prevented the barrier-disrupting effect of thrombin on the endothelial monolayer, as it was visualized by VEcadherin staining. Selective blocking of EP 4 receptors (EP 4 antagonist ONO-AE3-208) inhibited the protective effect of PGE 2 on endothelial monolayers. PGE 2 and the EP 4 agonist enhanced the regeneration of electrically wounded endothelial monolayers. The specificity of EP 4 receptor involvement was proven by using the EP 4 receptor antagonist and selective agonists for EP 2 and EP 3 receptors. PGE 2 and the EP 4 receptor agonist attenuated the TNF-α-induced up-regulation of E-selectin. Surprisingly, this effect was not affected by an adenylyl cyclase inhibitor, but inhibition of PKC activity reversed the effect of the EP 4 receptor agonist and PGE 2 at reducing the E-selectin expression. In the cell interaction assays, thrombin or TNF-α increased the permeability of endothelial monolayers which also enhanced the transmigration of neutrophils and eosinophils, respectively. These effects were prevented by the selective activation of EP 4 receptors.
Conclusions
Our data support the hypothesis that endothelial cells, as gate-keepers of the vessel wall can actively participate in the inflammatory process. We have shown that PGE 2 , via activating EP 4 receptors, enhances the barrier function of the endothelium by protecting the endothelial adherent junctional network and preventing leukocyte diapedesis. Therefore, EP 4 agonists might be promising new therapeutic tools in treating inflammatory diseases.
